Congratulations to KP Smith on being award an NRSA F32 postdoctoral fellowship..
0 Comments
We are delighted that Kate will be joining the laboratory in February as a postdoctoral fellow after obtaining her PhD degree from the Department of Microbiology and Immunology at the University of North Carolina at Chapel Hill. She currently studies protein export and virulence in Mycobacterium tuberculosis in the laboratory of Miriam Braunstein.
on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 6-8, 2017. Posters were on apramycin, inkjet printer-based susceptibility testing methodology, and MAST rapid susceptibility technology, respectively.
Smith KP, Richmond DL, Brennan-Krohn T, Elliott HL, Kirby JE. Development of MAST: a Microscopy-Based Antimicrobial Susceptibility Testing Platform. SLAS Technology, In press.
Use of inkjet printing, advanced imaging, and machine learning to achieve reference standard, microdilution antimicrobial susceptibility testing readout in two hours with off-the-shelf supplies. For any antimicrobial at will. Update: Now Published On-Line in SLAS Technology Website!
.On acceptance of her manuscript by the Journal of Antimicrobial Chemotherapy:
Brennan-Krohn T, Truelson KA, Smith KP, Kirby JE. Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology. J Antimicrobial Chemotherapy. 2017 July. Link to abstract. Link to Journal Full Text. Please read this informative blog post by clinical microbiology and postdoctoral fellow, Thea Brennan-Krohn: "AST FOR NEW ANTIBIOTICS: THE CLINICAL LABORATORIAN'S DILEMMA."
The manuscript highlights the remarkable activity of apramycin against multidrug-resistant, extensively drug resistant and pandrug-resistant Acinetobacter and Pseudomonas. Both organisms are significant multidrug-resistance threats. Importantly, frank resistance to apramycin was observed in < 2% of isolates. Apramycin is an aminocyclitol-based aminoglycoside that is currently approved for veterinary use. The activity in these groups of bacteria was especially notable in light of the high level of resistance of the same strain set to aminoglycosides (amikacin, gentamicin, tobramycin) approved for human use. This study complements our prior study, also published in DMID, demonstrating activity of apramycin against a high proportion of carbapenem-resistant Enterobacteriaceae strains.
Published online today in Infection and Immunity: "Promotion and Rescue of Intracellular Brucella neotomae Replication During Co-Infection With Legionella pneumophila." Yoon-Suk created a versatile bioreporter toolkit to enable analysis of the fate of individual pathogens in polymicrobial infections. He then validated a type IV secretion system-dependent Brucella model using the wood rat pathogen, Brucella neotomae. In contrast to wild type organisms, Brucella T4SS mutants were completely defective in their ability to growth inside of macrophages. Fascinatingly co-infection with Legionella pneumophila, another T4SS-dependent pathogen, was able to rescue intracellular growth of the T4SS-mutant Brucella and also stimulated growth of wild type Brucella organisms! This was a one way rescue: Legionella could rescue Brucella, but wild type Brucellla could not rescue T4SS-defective Legionella.
|
Kirby Lab Blog Categories
All
Archives
January 2024
|